Total buying$00 buys
DNA
Ginkgo Bioworks Holdings, Inc.
NYSEHealthcareBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Insider activity for last month from 10/02 to 11/02.
How these metrics are calculated
Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total selling$1.34M7 sells
Net open-market−$1.34MBuying minus selling
Active insiders4Distinct reporting owners
Insider activity report
Calendar-month buckets within the selected date range
Latest filing: Oct 21, 2026
Open-market transaction mix · 7 transactions in the selected period
Code A includes awards, grants and other acquisitions; these are not open-market buys. A rolling period can include partial calendar months.
View exact monthly counts and disclosed values
| Month | Buys | Sells | Awards (A) | Buy value | Sell value | Net P/S value |
|---|---|---|---|---|---|---|
| Oct 2026 | 0 | 7 | 0 | $0 | $1.34M | -$1.34M |
| Nov 2026 | 0 | 0 | 0 | $0 | $0 | $0 |
Distinct insiders active
Reporting-owner CIKs by month · peak Oct 2026 (4)Oct 2026Nov 2026
Largest insider activity
By absolute net disclosed value · current transaction page- CP—
- CB—
- SP—
DNA transaction history
Newest filings · 20 transactions per pageLatest insider transactions
Form 4 filings from last month.| Company | Insider | Activity | Disclosed value | Filed (ET) |
|---|---|---|---|---|
DNAGinkgo Bioworks Holdings, Inc. | Coen Steven P.SR | M · exerciseDerivative securitySEC filing ↗ | UnknownView disclosure → | |
DNAGinkgo Bioworks Holdings, Inc. | Coen Steven P.SR | M · exerciseDerivative securitySEC filing ↗ | UnknownView disclosure → | |
DNAGinkgo Bioworks Holdings, Inc. | Coen Steven P.SR | S · saleSEC filing ↗ | -$7.76kView disclosure → | |
DNAGinkgo Bioworks Holdings, Inc. | Coen Steven P.SR | M · exerciseSEC filing ↗ | UnknownView disclosure → | |
DNAGinkgo Bioworks Holdings, Inc. | Coen Steven P.SR | M · exerciseSEC filing ↗ | UnknownView disclosure → | |
DNAGinkgo Bioworks Holdings, Inc. | Canton Barry10% | M · exerciseDerivative securitySEC filing ↗ | UnknownView disclosure → | |
DNAGinkgo Bioworks Holdings, Inc. | Canton Barry10% | M · exerciseDerivative securitySEC filing ↗ | UnknownView disclosure → | |
DNAGinkgo Bioworks Holdings, Inc. | Canton Barry10% | M · exerciseDerivative securitySEC filing ↗ | UnknownView disclosure → | |
DNAGinkgo Bioworks Holdings, Inc. | Canton Barry10% | M · exerciseDerivative securitySEC filing ↗ | UnknownView disclosure → | |
DNAGinkgo Bioworks Holdings, Inc. | Canton Barry10% | S · saleSEC filing ↗ | -$226kView disclosure → | |
DNAGinkgo Bioworks Holdings, Inc. | Canton Barry10% | M · exerciseSEC filing ↗ | UnknownView disclosure → | |
DNAGinkgo Bioworks Holdings, Inc. | Canton Barry10% | M · exerciseSEC filing ↗ | UnknownView disclosure → | |
DNAGinkgo Bioworks Holdings, Inc. | Canton Barry10% | S · saleSEC filing ↗ | -$190kView disclosure → | |
DNAGinkgo Bioworks Holdings, Inc. | Canton Barry10% | M · exerciseSEC filing ↗ | UnknownView disclosure → | |
DNAGinkgo Bioworks Holdings, Inc. | Canton Barry10% | M · exerciseSEC filing ↗ | UnknownView disclosure → | |
DNAGinkgo Bioworks Holdings, Inc. | Shetty Reshma P.SR | M · exerciseDerivative securitySEC filing ↗ | UnknownView disclosure → | |
DNAGinkgo Bioworks Holdings, Inc. | Shetty Reshma P.SR | M · exerciseDerivative securitySEC filing ↗ | UnknownView disclosure → | |
DNAGinkgo Bioworks Holdings, Inc. | Shetty Reshma P.SR | M · exerciseDerivative securitySEC filing ↗ | UnknownView disclosure → | |
DNAGinkgo Bioworks Holdings, Inc. | Shetty Reshma P.SR | M · exerciseDerivative securitySEC filing ↗ | UnknownView disclosure → | |
DNAGinkgo Bioworks Holdings, Inc. | Shetty Reshma P.SR | S · saleSEC filing ↗ | -$190kView disclosure → |
Filing-only signals
Deterministic matches in the selected period
Filing detail checks
Secondary metrics for the selected periodTransaction codes
By Form 4 transaction code in selected period31transactionstxns
- M · Option exercise · dominant24 · 77%
- S · Open-market sells7 · 23%
Activity by reported role
A joint filing can contribute to multiple rolesSR21
10% owner10
Reported Holdings After
Separated by insider, security, and ownership type
Coen Steven P.Class A Common Stock · Direct
50,168Oct 19, 2026
Kelly Jason RClass A Common Stock · Direct
129,065Oct 19, 2026
Shetty Reshma P.Class A Common Stock · Direct
453,951Oct 19, 2026
Shetty Reshma P.Class A Common Stock · Indirect · By Spouse
356,329Oct 19, 2026
Canton BarryClass A Common Stock · Direct
356,329Oct 19, 2026
Canton BarryClass A Common Stock · Indirect · By Spouse
453,951Oct 19, 2026
Kelly Jason RRestricted Stock Units · Direct
283,677Oct 16, 2026
Shetty Reshma P.Restricted Stock Units · Direct
116,804Oct 16, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Current transaction page only · each cell is a filing date · buys green, sells redOct 02 → Nov 02
LessMore
Ginkgo Bioworks Holdings, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Ginkgo Bioworks Holdings, Inc.?
Coen Steven P., Canton Barry, Shetty Reshma P., Kelly Jason R.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Coen Steven P. reported a sale on Oct 19, 2026 valued at $7.76k. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $1,342,382.27. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.